{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:19:56Z","timestamp":1784225996749,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bpobgyn.2023.102437","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T19:33:13Z","timestamp":1700940793000},"page":"102437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pharmacogenomics of Preeclampsia therapies: Current evidence and future challenges for clinical implementation"],"prefix":"10.1016","volume":"92","author":[{"given":"Piya","family":"Chaemsaithong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-7701","authenticated-orcid":false,"given":"Mohitosh","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waranyu","family":"Lertrut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puntabut","family":"Warintaksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuangsit","family":"Wataganara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liona CY.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2023.102437_bib1","doi-asserted-by":"crossref","first-page":"S786","DOI":"10.1016\/j.ajog.2021.12.001","article-title":"Preeclampsia and eclampsia: the conceptual evolution of a syndrome","volume":"226","author":"Erez","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib2","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.ajog.2021.11.1356","article-title":"The etiology of preeclampsia","volume":"226","author":"Jung","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-023-00417-6","article-title":"Pre-eclampsia","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","article-title":"Pre-eclampsia","volume":"398","author":"Chappell","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(15)00070-7","article-title":"Pre-eclampsia","volume":"387","author":"Mol","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","article-title":"The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice","volume":"27","author":"Magee","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib8","series-title":"Author Correction: pre-eclampsia: pathogenesis, novel diagnostics and therapies","first-page":"386","author":"Phipps","year":"2019"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib9","doi-asserted-by":"crossref","first-page":"l2381","DOI":"10.1136\/bmj.l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"Burton","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib10","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1126\/science.1111726","article-title":"Latest advances in understanding preeclampsia","volume":"308","author":"Redman","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"Sibai","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2215\/CJN.12081115","article-title":"Preeclampsia: updates in pathogenesis, definitions, and guidelines","volume":"11","author":"Phipps","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.semnephrol.2017.05.011","article-title":"Preeclampsia: pathogenesis, prevention, and long-term complications","volume":"37","author":"Jim","year":"2017","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.12688\/f1000research.12249.1","article-title":"Recent advances in the diagnosis and management of pre-eclampsia","volume":"7","author":"Duhig","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib16","doi-asserted-by":"crossref","first-page":"S1108","DOI":"10.1016\/j.ajog.2020.08.045","article-title":"Prevention of preeclampsia with aspirin","volume":"226","author":"Rolnik","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib17","doi-asserted-by":"crossref","first-page":"569.e1","DOI":"10.1016\/j.ajog.2022.11.001","article-title":"Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood","volume":"228","author":"Chaiworapongsa","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/uog.22107","article-title":"Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: systematic review and meta-analysis","volume":"57","author":"Dall'Asta","year":"2021","journal-title":"Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/uog.18899","article-title":"Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol. England"},{"issue":"2","key":"10.1016\/j.bpobgyn.2023.102437_bib21","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2023.04.039","article-title":"Society for Maternal-Fetal Medicine Special Statement: prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement","volume":"229","author":"Combs","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ajog.2022.09.046","article-title":"Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis","volume":"228","author":"Richards","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajog.2017.11.561","article-title":"Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis","volume":"218","author":"Roberge","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajog.2018.03.018","article-title":"Optimal aspirin dosing for preeclampsia prevention","volume":"219","author":"Seidler","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pharmthera.2017.02.036","article-title":"Personalized medicine: genetic risk prediction of drug response","volume":"175","author":"Zhang","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1742-7843.2012.00905.x","article-title":"Effects of matrix metalloproteinase (MMP)-2 polymorphisms on responsiveness to antihypertensive therapy of women with hypertensive disorders of pregnancy","volume":"111","author":"Palei","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib27","first-page":"37","article-title":"The role of genetics in pre-eclampsia and potential pharmacogenomic interventions","volume":"5","author":"Williams","year":"2012","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-3476(95)70277-6","article-title":"Use of glucagon to treat neonatal low-output congestive heart failure after maternal labetalol therapy","volume":"127","author":"Stevens","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib29","first-page":"371","article-title":"Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy","volume":"1","author":"Garden","year":"1982","journal-title":"Clin Exp Hypertens B"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib30","first-page":"328","article-title":"A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy","volume":"70","author":"Mabie","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2006.02.015","article-title":"Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial","volume":"128","author":"Vigil-De Gracia","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib32","doi-asserted-by":"crossref","first-page":"l5119","DOI":"10.1136\/bmj.l5119","article-title":"Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance","volume":"366","author":"Webster","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.496","article-title":"Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology","volume":"7","author":"\u00c5gesen","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of veterans affairs cooperative study group on antihypertensive agents","volume":"328","author":"Materson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005344-200202000-00001","article-title":"Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking","volume":"39","author":"Rathz","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0009-9236(03)00068-7","article-title":"Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","article-title":"Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects","volume":"3","author":"MacCarthy","year":"1983","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib38","first-page":"85","article-title":"CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors","volume":"6","author":"Sukasem","year":"2013","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib39","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jcph.1685","article-title":"Clinical experiences of intravenous hydralazine and labetalol for acute treatment of severe hypertension in pregnant Thai women","volume":"60","author":"Chera-Aree","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib40","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of beta-blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib41","doi-asserted-by":"crossref","first-page":"576","DOI":"10.35755\/jmedassocthai.2021.04.11795","article-title":"A 13-year review of eclampsia and anesthetic techniques at a single tertiary care center","volume":"104","author":"Wongsripuemtet","year":"2021","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/14622416.7.3.271","article-title":"CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension","volume":"7","author":"Bremer","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib43","first-page":"275","article-title":"Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic","volume":"30","author":"Haas","year":"2013","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib44","first-page":"16S","article-title":"Supraventricular tachycardia in pregnancy: cardioversion with verapamil","volume":"63","author":"Klein","year":"1984","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/00000539-200207000-00009","article-title":"Profound sinus bradycardia after intravenous nicardipine","volume":"95","author":"Arima","year":"2002","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1161\/CIRCGENETICS.110.957654","article-title":"Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)","volume":"3","author":"Niu","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib47","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/bcp.13649","article-title":"Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials","volume":"84","author":"Sridharan","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib48","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/jcph.1477","article-title":"Effect of N-acetyltransferase 2 genotype on the pharmacokinetics of hydralazine during pregnancy","volume":"59","author":"Han","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib49","first-page":"1","article-title":"Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment","volume":"94","author":"Burroughs","year":"2002","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib50","first-page":"151","article-title":"Pharmacogenetics of antihypertensive drug responses","volume":"4","author":"Schwartz","year":"2004","journal-title":"Am J pharmacogenomics genomics-related Res drug Dev Clin Pract."},{"key":"10.1016\/j.bpobgyn.2023.102437_bib51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1159\/000510433","article-title":"Genotype-guided hydralazine therapy","volume":"51","author":"Collins","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib52","first-page":"203","article-title":"Genetic polymorphisms, drug metabolism and drug concentrations","volume":"25","author":"Shenfield","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1353\/hub.2007.0041","article-title":"Importance of acetylator phenotype in the identity of Asian populations","volume":"79","author":"Zaid","year":"2007","journal-title":"Hum Biol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2217\/pgs-2016-0198","article-title":"Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives","volume":"18","author":"Luizon","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00404-018-4791-8","article-title":"Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy","volume":"298","author":"Sun","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/uog.18816","article-title":"ASPRE trial: performance of screening for preterm pre-eclampsia","volume":"50","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib57","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jch.12541","article-title":"Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis","volume":"17","author":"Xu","year":"2015","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247782","article-title":"Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: a systematic review and meta-analysis","volume":"16","author":"Van Doorn","year":"2021","journal-title":"PLoS One"},{"issue":"92","key":"10.1016\/j.bpobgyn.2023.102437_bib59","article-title":"Prediction of preeclampsia in asymptomatic women","volume":"23","author":"Lee","year":"2023","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib60","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.2174\/138161212803251907","article-title":"Pharmacogenetics of the antiplatelet effect of aspirin","volume":"18","author":"W\u00fcrtz","year":"2012","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gene.2013.04.083","article-title":"The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin","volume":"526","author":"Al-Azzam","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","article-title":"Pharmacogenetics of aspirin resistance: a comprehensive systematic review","volume":"66","author":"Goodman","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/14622416.8.6.577","article-title":"Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin","volume":"8","author":"Li","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1756285616681943","article-title":"Interactions among COX-2, GPIIIa and P2Y1 variants are associated with aspirin responsiveness and adverse events in patients with ischemic stroke","volume":"10","author":"Yi","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib65","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejogrb.2020.09.036","article-title":"Aspirin non-response in pregnant women at increased risk of pre-eclampsia","volume":"254","author":"Vinogradov","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib66","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/1471-0528.13914","article-title":"Low dose aspirin and pregnancy: how important is aspirin resistance?","volume":"123","author":"Navaratnam","year":"2016","journal-title":"BJOG"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/tpj.2016.35","article-title":"Gene-gene interactions in the NAMPT pathway, plasma visfatin\/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy","volume":"17","author":"Luizon","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/pgs-2021-0006","article-title":"NAMPT single-nucleotide polymorphism rs1319501 and visfatin\/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia","volume":"22","author":"Pereira","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib69","article-title":"New insights into the role of matrix metalloproteinases in preeclampsia","volume":"18","author":"Espino","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib70","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/tpj.2011.31","article-title":"Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy","volume":"12","author":"Palei","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/tpj.2009.38","article-title":"eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension","volume":"10","author":"Sandrim","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib72","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/tpj.2014.26","article-title":"Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy","volume":"14","author":"Luizon","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib73","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00404-014-3475-2","article-title":"Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms","volume":"291","author":"Sandrim","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fsoc.2023.1112159","article-title":"Precision and personalized medicine: what their current definition says and silences about the model of health they promote. Implication for the development of personalized health","volume":"8","author":"Delpierre","year":"2023","journal-title":"Front Sociol"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.trsl.2009.09.005","article-title":"Genomic and personalized medicine: foundations and applications","volume":"154","author":"Ginsburg","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.bpobgyn.2023.102437_bib76","first-page":"1293","article-title":"Strategy for standardization of preeclampsia research study design","volume":"63","author":"Myatt","year":"2014","journal-title":"Hypertension (New York)"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169342300144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169342300144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:16:16Z","timestamp":1761498976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169342300144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":76,"alternative-id":["S152169342300144X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2023.102437","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics of Preeclampsia therapies: Current evidence and future challenges for clinical implementation","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2023.102437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102437"}}